Prelude Therapeutics (PRLD) Competitors $0.96 -0.08 (-7.68%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.97 +0.01 (+0.61%) As of 06/13/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. ENGN, SCPH, CTMX, DRUG, CRGX, IPHA, NBTX, TIL, SOPH, and BTMDShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include enGene (ENGN), scPharmaceuticals (SCPH), CytomX Therapeutics (CTMX), Bright Minds Biosciences (DRUG), CARGO Therapeutics (CRGX), Innate Pharma (IPHA), Nanobiotix (NBTX), Instil Bio (TIL), SOPHiA GENETICS (SOPH), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Its Competitors enGene scPharmaceuticals CytomX Therapeutics Bright Minds Biosciences CARGO Therapeutics Innate Pharma Nanobiotix Instil Bio SOPHiA GENETICS biote enGene (NASDAQ:ENGN) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings. Do analysts recommend ENGN or PRLD? enGene currently has a consensus target price of $23.29, indicating a potential upside of 599.27%. Prelude Therapeutics has a consensus target price of $4.00, indicating a potential upside of 316.62%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk & volatility, ENGN or PRLD? enGene has a beta of -0.4, meaning that its share price is 140% less volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Is ENGN or PRLD more profitable? enGene's return on equity of -16.69% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -16.69% -14.27% Prelude Therapeutics N/A -66.89%-55.59% Does the MarketBeat Community favor ENGN or PRLD? Prelude Therapeutics received 13 more outperform votes than enGene when rated by MarketBeat users. However, 95.24% of users gave enGene an outperform vote while only 51.56% of users gave Prelude Therapeutics an outperform vote. CompanyUnderperformOutperformenGeneOutperform Votes2095.24% Underperform Votes14.76%Prelude TherapeuticsOutperform Votes3351.56% Underperform Votes3148.44% Which has preferable earnings & valuation, ENGN or PRLD? enGene has higher earnings, but lower revenue than Prelude Therapeutics. enGene is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.52-2.19Prelude Therapeutics$7M7.74-$121.83M-$1.69-0.57 Do insiders and institutionals hold more shares of ENGN or PRLD? 64.2% of enGene shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 10.4% of enGene shares are held by insiders. Comparatively, 63.9% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to ENGN or PRLD? In the previous week, enGene had 13 more articles in the media than Prelude Therapeutics. MarketBeat recorded 14 mentions for enGene and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.83 beat enGene's score of -0.17 indicating that Prelude Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment enGene Neutral Prelude Therapeutics Very Positive SummaryenGene beats Prelude Therapeutics on 10 of the 17 factors compared between the two stocks. Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRLD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.21M$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E Ratio-0.548.4626.7519.65Price / Sales7.74261.91403.98152.07Price / CashN/A65.8538.2534.64Price / Book0.226.526.964.59Net Income-$121.83M$143.26M$3.23B$248.23M7 Day Performance-6.79%-0.21%-1.22%-1.07%1 Month Performance2.47%10.62%6.34%2.59%1 Year Performance-75.38%3.63%33.05%13.50% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.0781 of 5 stars$0.96-7.7%$4.00+316.6%-75.4%$54.21M$7M-0.54120Positive NewsGap DownENGNenGene2.4481 of 5 stars$3.98+3.6%$23.29+485.1%-63.0%$202.89MN/A-6.8631News CoverageEarnings ReportSCPHscPharmaceuticals4.3484 of 5 stars$3.84+5.5%$14.00+264.6%-4.6%$202.72M$41.98M-2.0230Positive NewsCTMXCytomX Therapeutics4.2735 of 5 stars$2.51-5.3%$5.33+112.5%+99.3%$202.36M$147.56M14.76170Positive NewsDRUGBright Minds Biosciences3.3161 of 5 stars$28.32+9.1%$83.25+194.0%+2,526.7%$199.49MN/A-166.58N/APositive NewsAnalyst RevisionGap DownCRGXCARGO Therapeutics2.38 of 5 stars$4.28+0.7%$15.00+250.5%-73.7%$197.35MN/A-1.00116Positive NewsIPHAInnate Pharma3.1336 of 5 stars$2.14-2.2%$11.00+413.8%-19.4%$197.35M$12.62M0.00220NBTXNanobiotix2.863 of 5 stars$4.13+0.8%$8.00+93.5%+12.0%$194.85M-$11.61M0.00100Short Interest ↓Gap UpTILInstil Bio3.0077 of 5 stars$29.65+10.0%$112.33+278.9%+227.9%$194.47MN/A-2.56410Short Interest ↑Gap DownHigh Trading VolumeSOPHSOPHiA GENETICS1.7995 of 5 stars$2.91-3.0%$6.80+133.7%-40.6%$194.06M$67.17M-2.67520News CoveragePositive NewsBTMDbiote3.839 of 5 stars$3.54+2.3%$8.00+126.0%-40.8%$193.67M$199.38M13.62194 Related Companies and Tools Related Companies enGene Alternatives scPharmaceuticals Alternatives CytomX Therapeutics Alternatives Bright Minds Biosciences Alternatives CARGO Therapeutics Alternatives Innate Pharma Alternatives Nanobiotix Alternatives Instil Bio Alternatives SOPHiA GENETICS Alternatives biote Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRLD Stock Free PRLD Stock Alerts